You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hardaker E, Karmokar A, Milo M, et al
877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0877